{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:12:55Z","timestamp":1792141975806,"version":"4.4.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To lower treatment-related mortality and toxicity of conventional marrow transplantation, a nonmyeloablative regimen using 200 cGy total-body irradiation (TBI) and mycophenolate mofetil (MMF) combined with cyclosporine (CSP) for postgrafting immunosuppression was developed. To circumvent possible toxic effects of external-beam \u03b3 irradiation, strategies for targeted radiation therapy were investigated. We tested whether the short-lived (half-life, 46 minutes) \u03b1-emitter bismuth 213 (213Bi) conjugated to an anti-CD45 monoclonal antibody (mAb) could replace 200 cGy TBI and selectively target hematopoietic tissues in a canine model of nonmyeloablative DLA-identical marrow transplantation. Biodistribution studies using iodine 123\u2013labeled anti-CD45 mAb showed uptake in blood, marrow, lymph nodes, spleen, and liver. In a dose-escalation study, 7 dogs treated with the 213Bi\u2013anti-CD45 conjugate (213Bi dose, 0.1-5.9 mCi\/kg [3.7-218 MBq\/kg]) without marrow grafts had no toxic effects other than a mild, reversible suppression of blood counts. On the basis of these studies, 3 dogs were treated with 0.5 mg\/kg 213Bi-labeled anti-CD45 mAb (213Bi doses, 3.6, 4.6, and 8.8 mCi\/kg [133, 170, and 326 MBq\/kg]) given in 6 injections 3 and 2 days before grafting of marrow from DLA-identical littermates. The dogs also received MMF (10 mg\/kg subcutaneously twice daily the day of transplantation until day 27 afterward) and CSP (15 mg\/kg orally twice daily the day before transplantation until 35 days afterward). The therapy was well tolerated except for transient elevations in levels of transaminases in 3 dogs, followed by, in one dog, ascites. All dogs had prompt engraftment and achieved stable mixed hematopoietic chimerism, with donor contributions ranging from 30% to 70% after more than 27 weeks of follow-up. These results will form the basis for additional studies in animals and later the design of clinical trials using213Bi as a nonmyeloablative conditioning regimen with minimal toxicity.<\/jats:p>","DOI":"10.1182\/blood-2001-12-0322","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T14:33:52Z","timestamp":1034346832000},"page":"318-326","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["Bismuth 213\u2013labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts"],"prefix":"10.1182","volume":"100","author":[{"given":"Brenda M.","family":"Sandmaier","sequence":"first","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Bethge","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Wilbur","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald K.","family":"Hamlin","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlinda B.","family":"Santos","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; the Departments of Medicine and Radiation Oncology, University of Washington, Seattle; the National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223115104800_B1","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","article-title":"Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.","volume":"89","author":"Storb","year":"1997","journal-title":"Blood."},{"key":"2020021223115104800_B2","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood."},{"key":"2020021223115104800_B3","first-page":"109","article-title":"Radioisotope-mediated purging in bone marrow transplantation.","volume":"333","author":"Macklis","year":"1990","journal-title":"Prog Clin Biol Res."},{"key":"2020021223115104800_B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-4615-6349-5_6","article-title":"The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies.","volume":"77","author":"Matthews","year":"1997","journal-title":"Cancer Treat Res."},{"key":"2020021223115104800_B5","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood.V78.7.1864.1864","article-title":"Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque.","volume":"78","author":"Matthews","year":"1991","journal-title":"Blood."},{"key":"2020021223115104800_B6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","article-title":"Phase I study of 131I\u2013anti-CD45 antibody plus cyclophosphamide and total-body irradiation for advanced acute leukemia and myelodysplastic syndrome.","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood."},{"key":"2020021223115104800_B7","first-page":"194","article-title":"\u03b1-particle emitters in medicine.","volume-title":"Dosimetry of Administered Radionuclides.","author":"Fisher","year":"1989"},{"key":"2020021223115104800_B8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s002590050306","article-title":"Radioimmunotherapy with \u03b1-emitting nuclides.","volume":"25","author":"McDevitt","year":"1998","journal-title":"Eur J Nucl Med."},{"key":"2020021223115104800_B9","first-page":"85","article-title":"Potential use of \u03b1-emitting radionuclides in the treatment of cancer.","volume":"4","author":"Wilbur","year":"1991","journal-title":"Antibody Immunoconjugates Radiopharm."},{"key":"2020021223115104800_B10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/02841869609101654","article-title":"Radioimmunotherapy with \u03b1-particle emitting radioimmunoconjugates.","volume":"35","author":"Zalutsky","year":"1996","journal-title":"Acta Oncol."},{"key":"2020021223115104800_B11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.2897133","article-title":"Radioimmunotherapy with \u03b1-particle-emitting immunoconjugates.","volume":"240","author":"Macklis","year":"1988","journal-title":"Science."},{"key":"2020021223115104800_B12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2307\/3578139","article-title":"Radiobiology of \u03b1 particles, III: cell inactivation by \u03b1-particle traversals of the cell nucleus.","volume":"128","author":"Raju","year":"1991","journal-title":"Radiat Res."},{"key":"2020021223115104800_B13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00008390-200010030-00011","article-title":"Radioimmunoconjugates for targeted \u03b1 therapy of malignant melanoma.","volume":"10","author":"Abbas Rizvi","year":"2000","journal-title":"Melanoma Res."},{"key":"2020021223115104800_B14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0969-8051(00)00103-7","article-title":"Delivery of the \u03b1-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.","volume":"27","author":"Adams","year":"2000","journal-title":"Nucl Med Biol."},{"key":"2020021223115104800_B15","first-page":"43","article-title":"Selective ablation of B-lymphocytes in vivo by \u03b1 emitter, 212bismuth, chelated to a monoclonal antibody.","volume":"1","author":"Black","year":"1988","journal-title":"Antibody Immunoconjugates Radiopharm."},{"key":"2020021223115104800_B16","first-page":"5818","article-title":"Effective \u03b1-particle-mediated radioimmunotherapy of murine leukemia.","volume":"52","author":"Huneke","year":"1992","journal-title":"Cancer Res."},{"key":"2020021223115104800_B17","first-page":"6095","article-title":"An \u03b1-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.","volume":"60","author":"McDevitt","year":"2000","journal-title":"Cancer Res."},{"key":"2020021223115104800_B18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy with targeted atomic nanogenerators.","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science."},{"key":"2020021223115104800_B19","first-page":"1935","article-title":"Pharmacokinetics and dosimetry of an \u03b1-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.","volume":"40","author":"Sgouros","year":"1999","journal-title":"J Nucl Med."},{"key":"2020021223115104800_B20","first-page":"S65","article-title":"Phase I trial of astatine-211 labeled human\/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities [abstract].","volume":"1","author":"Zalutsky","year":"1999","journal-title":"Neuro-oncology"},{"key":"2020021223115104800_B21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1084\/jem.152.4.842","article-title":"Human homologue of murine T200 glycoprotein.","volume":"152","author":"Omary","year":"1980","journal-title":"J Exp Med."},{"key":"2020021223115104800_B22","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0968-0896(97)00130-2","article-title":"Stereochemical influence on the stability of radio-metal complexes in vivo: synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA.","volume":"5","author":"Wu","year":"1997","journal-title":"Bioorg Med Chem."},{"key":"2020021223115104800_B23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00007890-199609270-00032","article-title":"Histocompatibility testing of dog families with highly polymorphic microsatellite markers.","volume":"62","author":"Wagner","year":"1996","journal-title":"Transplantation."},{"key":"2020021223115104800_B24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1399-0039.1998.tb03063.x","article-title":"DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing.","volume":"52","author":"Wagner","year":"1998","journal-title":"Tissue Antigens."},{"key":"2020021223115104800_B25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/030098589603300210","article-title":"Canine lymphoma: immunocytochemical analysis of fine-needle aspiration biopsy.","volume":"33","author":"Caniatti","year":"1996","journal-title":"Vet Pathol."},{"key":"2020021223115104800_B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1399-0039.1992.tb01963.x","article-title":"Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils.","volume":"40","author":"Moore","year":"1992","journal-title":"Tissue Antigens."},{"key":"2020021223115104800_B27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00007890-199905270-00007","article-title":"The use of an anti-TCR \u03b1 \u03b2 monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation.","volume":"67","author":"Barsoukov","year":"1999","journal-title":"Transplantation."},{"key":"2020021223115104800_B28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V76.3.630.630","article-title":"An antibody that facilitates hematopoietic engraftment recognizes CD44.","volume":"76","author":"Sandmaier","year":"1990","journal-title":"Blood."},{"key":"2020021223115104800_B29","first-page":"125","article-title":"Biochemical characterization of a unique canine myeloid antigen.","volume":"5","author":"Sandmaier","year":"1991","journal-title":"Leukemia."},{"key":"2020021223115104800_B30","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.4049\/jimmunol.135.3.2183","article-title":"Influence of antibody isotype on passive serotherapy of lymphoma.","volume":"135","author":"Denkers","year":"1985","journal-title":"J Immunol."},{"key":"2020021223115104800_B31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0165-2427(93)90075-F","article-title":"Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species.","volume":"39","author":"Jacobsen","year":"1993","journal-title":"Vet Immunol Immunopathol."},{"key":"2020021223115104800_B32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/bc00016a014","article-title":"Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates.","volume":"3","author":"Pippin","year":"1992","journal-title":"Bioconjug Chem."},{"key":"2020021223115104800_B33","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood.V91.9.3494","article-title":"Epitope specificity of CD44 for monoclonal antibody\u2013dependent facilitation of marrow engraftment in a canine model.","volume":"91","author":"Sandmaier","year":"1998","journal-title":"Blood."},{"key":"2020021223115104800_B34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1399-0039.1983.tb00185.x","article-title":"The canine major histocompatibility complex: population study of DLA-D alleles using a panel of homozygous typing cells.","volume":"21","author":"Raff","year":"1983","journal-title":"Tissue Antigens."},{"key":"2020021223115104800_B35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0008-8749(85)90309-0","article-title":"Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage.","volume":"95","author":"Loughran","year":"1985","journal-title":"Cell Immunol."},{"key":"2020021223115104800_B36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0360-3016(93)90207-C","article-title":"Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model.","volume":"26","author":"Storb","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2020021223115104800_B37","first-page":"929","article-title":"Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a \u201ccold\u201d antibody pretreatment dose on marrow localization.","volume":"17","author":"Bianco","year":"1989","journal-title":"Exp Hematol."},{"key":"2020021223115104800_B38","first-page":"11","article-title":"Canine models of bone marrow transplantation.","volume":"40","author":"Ladiges","year":"1990","journal-title":"Lab Anim Sci."},{"key":"2020021223115104800_B39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00007890-199409270-00011","article-title":"Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting.","volume":"58","author":"Yu","year":"1994","journal-title":"Transplantation."},{"key":"2020021223115104800_B40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/carcin\/13.8.1475","article-title":"Storage phosphor imaging technique for detection and quantitation of DNA adducts measured by the 32P-postlabeling assay.","volume":"13","author":"Reichert","year":"1992","journal-title":"Carcinogenesis."},{"key":"2020021223115104800_B41","first-page":"1228","article-title":"Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.","volume":"52","author":"Matthews","year":"1992","journal-title":"Cancer Res."},{"key":"2020021223115104800_B42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.V98.3.565","article-title":"Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.","volume":"98","author":"Bunjes","year":"2001","journal-title":"Blood."},{"key":"2020021223115104800_B43","first-page":"5126","article-title":"Immunosuppressive effects of 131I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models.","volume":"61","author":"Ruffner","year":"2001","journal-title":"Cancer Res."},{"key":"2020021223115104800_B44","first-page":"2635","article-title":"High-linear energy transfer (LET) \u03b1 versus low-LET \u03b2 emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17\u20131A Fab\u2032 fragments in a human colonic cancer model.","volume":"59","author":"Behr","year":"1999","journal-title":"Cancer Res."},{"key":"2020021223115104800_B45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0969-8051(98)00069-9","article-title":"Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the \u03b1-particle emitter 213Bi.","volume":"26","author":"Kennel","year":"1999","journal-title":"Nucl Med Biol."},{"key":"2020021223115104800_B46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/cr000118y","article-title":"The development of the \u03b1-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications.","volume":"101","author":"Hassfjell","year":"2001","journal-title":"Chem Rev."},{"key":"2020021223115104800_B47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ajcp\/79.5.546","article-title":"Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia.","volume":"79","author":"Andres","year":"1983","journal-title":"Am J Clin Pathol."},{"key":"2020021223115104800_B48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0145-2126(87)90110-X","article-title":"Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome.","volume":"11","author":"Caldwell","year":"1987","journal-title":"Leuk Res."},{"key":"2020021223115104800_B49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev.iy.12.040194.000505","article-title":"CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development.","volume":"12","author":"Trowbridge","year":"1994","journal-title":"Annu Rev Immunol."},{"key":"2020021223115104800_B50","first-page":"99","article-title":"Radiolabeled CHXB-2E4 is stable in vivo and is a suitable immunoconjugate for testing \u03b1-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy.","volume":"7","author":"Tiffany","year":"1994","journal-title":"Antibody Immunoconjugates Radiopharm."},{"key":"2020021223115104800_B51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/108497801300189227","article-title":"In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.","volume":"16","author":"Milenic","year":"2001","journal-title":"Cancer Biother Radiopharm."},{"key":"2020021223115104800_B52","first-page":"166","article-title":"\u03b1-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.","volume":"40","author":"Nikula","year":"1999","journal-title":"J Nucl Med."},{"key":"2020021223115104800_B53","first-page":"829","article-title":"Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.","volume":"39","author":"Kobayashi","year":"1998","journal-title":"J Nucl Med."},{"key":"2020021223115104800_B54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(00)00132-3","article-title":"Antibody therapy for residual disease in acute myelogenous leukemia.","volume":"38","author":"Jurcic","year":"2001","journal-title":"Crit Rev Oncol Hematol."},{"key":"2020021223115104800_B55","first-page":"4221","article-title":"Improved in vivo stability and tumor targeting of bismuth-labeled antibody.","volume":"50","author":"Ruegg","year":"1990","journal-title":"Cancer Res."},{"key":"2020021223115104800_B56","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/00007890-198811000-00024","article-title":"Characterization of interstitial dendritic cells in human liver.","volume":"46","author":"Prickett","year":"1988","journal-title":"Transplantation."},{"key":"2020021223115104800_B57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/gast.2001.20947","article-title":"Immunology of the healthy liver: old questions and new insights.","volume":"120","author":"Mehal","year":"2001","journal-title":"Gastroenterology."},{"key":"2020021223115104800_B58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.510240128","article-title":"Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats.","volume":"24","author":"Johansson","year":"1996","journal-title":"Hepatology."},{"key":"2020021223115104800_B59","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer."},{"key":"2020021223115104800_B60","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction following gemtuzumab ozogamicin (Mylotarg).","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood."},{"key":"2020021223115104800_B61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment.","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2020021223115104800_B62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease).","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis."},{"key":"2020021223115104800_B63","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nm1101-1202","article-title":"Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy.","volume":"7","author":"Wielockx","year":"2001","journal-title":"Nat Med."},{"key":"2020021223115104800_B64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.510310224","article-title":"Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat.","volume":"31","author":"Wang","year":"2000","journal-title":"Hepatology."},{"key":"2020021223115104800_B65","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1016\/S0016-5085(01)80267-5","article-title":"Prevention of hepatic venocclusive disease in the rat by inhibition of matrix metalloproteinases [abstract].","volume":"120","author":"DeLeve","year":"2001","journal-title":"Gastroenterology."},{"key":"2020021223115104800_B66","first-page":"5832S","article-title":"Overview of studies on experimental radioimmunotherapy.","volume":"55","author":"Knox","year":"1995","journal-title":"Cancer Res."},{"key":"2020021223115104800_B67","first-page":"43","article-title":"Monoclonal antibody therapy of cancer.","volume":"26","author":"Weiner","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021223115104800_B68","first-page":"7a","article-title":"Phase I trial of targeted \u03b1-particle therapy for myeloid leukemias with bismuth-213-HuM195 (Anti-CD33) [abstract].","volume":"18","author":"Jurcic","year":"1999","journal-title":"J Clin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/1\/318\/1683816\/h81302000318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/1\/318\/1683816\/h81302000318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T13:05:34Z","timestamp":1733749534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/1\/318\/133969\/Bismuth-213labeled-antiCD45-radioimmunoconjugate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2001-12-0322","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7,1]]}}}